HOLOGIC INC
hologic.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q1 FY2026 10-Q, filed Jan 29, 2026. Its latest SEC filing is a SCHEDULE 13G from Apr 30, 2026.
10-Q for Q1 FY2026, filed Jan 29, 2026
The sections below describe the company as of the FY2025 annual report.
What Did They Do?
Sells disposable diagnostic and surgical products, along with medical imaging systems, for women’s health to clinical laboratories, hospitals and healthcare providers.
10-K for FY2025, filed Nov 18, 2025We are a developer, manufacturer and supplier of premium diagnostics products, medical imaging systems, and surgical products focused on…View ↗
Through our Diagnostics segment, we offer a wide range of diagnostic products, which are used primarily to aid in the screening and…View ↗
Our Breast Health segment offers a broad portfolio of solutions for breast imaging, biopsy, breast surgery and pathology. These solutions…View ↗
Our GYN Surgical products include our MyoSure hysteroscopic tissue removal system, our NovaSure endometrial ablation system, our Fluent…View ↗
How Did They Make Money?
Most money comes from disposable tests, assays and surgical supplies; product sales are tied to shipment or delivery, and U.S. customers typically pay within 30 days. Support and maintenance contracts and extended warranties bring in revenue over their term; installation, training and repairs are billed as performed.
10-K for FY2025, filed Nov 18, 2025The Company considers revenue to be earned when all of the following criteria are met: the Company has a contract with a customer that…View ↗
F-23 point in time. Revenue from support and maintenance contracts and extended warranty is recognized over time based on the period…View ↗
The Company recognizes a receivable when it has an unconditional right to payment, which represents the amount the Company expects to…View ↗
-
10-K for FY2025, filed Nov 18, 2025
FY2025 revenue by product or service ↗
$4.1B
-
10-K for FY2025, filed Nov 19, 2025
$4.1B ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Disposables
Sold outright
10-K for FY2025, filed Nov 18, 2025 |
64%
FY2022: 74%
|
Disposables, FY2025
$2.6B Sources
|
Sold outright |
|
Capital equipment, components and software
Sold outright
10-K for FY2025, filed Nov 18, 2025 |
16%
FY2022: 12%
|
Capital equipment, components and software, FY2025
$638.4M Sources
|
Sold outright |
|
Service
|
20%
FY2022: 13%
|
Service, FY2025
$825.5M Sources
|
|
|
Other
|
0.5%
FY2022: 0.4%
|
Other, FY2025
$18.9M Sources
|
Who Were Their Customers?
Clinical laboratories, hospitals and healthcare providers buy Hologic’s products. Sales are direct and through distributors or sales representatives; some U.S. regions use dealers, while international sales combine direct teams and distributors.
10-K for FY2025, filed Nov 18, 2025We sell and service our products through a combination of direct sales and service forces and a network of independent distributors and…View ↗
Our U.S. sales force is structured to specifically target the customers in each of our business segments. We maintain distinct teams…View ↗
A critical element of our strategy in the U.S. for our Diagnostics, Breast Health, GYN Surgical, and Skeletal Health divisions has been to…View ↗
Did Revenues Turn Into Profits?
Yes. It kept 14 cents of every revenue dollar as net income in FY2025 and turned 24 cents into free cash flow.
10-K for FY2025, filed Nov 19, 2025
$714.3MView ↗
10-K for FY2025, filed Nov 19, 2025
$565.7MView ↗
10-K for FY2025, filed Nov 19, 2025
$998.3MView ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q1 FY2026, filed Jan 30, 2026
$179.1MView ↗
- ▼ −11%
- vs $201M in Q1 FY2025
-
Apr 7, 2026
Blackstone and TPG completed their acquisition of Hologic; Joe Almeida became CEO
Hologic became a private company, and its common stock ceased trading and was delisted from Nasdaq.
Sources
8-K, filed Apr 7, 2026
MARLBOROUGH, Mass. & NEW YORK & SAN FRANCISCO & FORT WORTH, Texas—(BUSINESS WIRE)— Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s…View ↗
Shrank. Revenue fell 27% in 4 years, from $5.6B in FY2021 to $4.1B in FY2025, about 8% a year.
Fluoroscan sales
The earlier report lists the Fluoroscan Insight FD mini C-arm among Skeletal Health products; the latest report says Hologic will discontinue its sale.
10-K for FY2022, filed Nov 15, 2022 10-K for FY2025, filed Nov 18, 2025Our Skeletal Health segment's products include the Horizon DXA, a dual energy x-ray system, which evaluates bone density and performs body…View ↗
Our Skeletal Health segment’s products include the Horizon DXA, a dual energy x-ray system, which evaluates bone density and performs body…View ↗
Who Did They Compete With?
Competes with Roche Diagnostics, Abbott Laboratories, Cepheid, Becton Dickinson, Siemens Healthineers, GE Healthcare, Johnson & Johnson, and Medtronic
10-K for FY2025, filed Nov 18, 2025In our Diagnostics business, our primary competitors include Roche Diagnostics, Abbott Laboratories and Cepheid in the molecular…View ↗
Loading...
